Prilenia Closes Oversubscribed $43 Million in Series B Financing Round – Winchester Herald Chronicle

Please log in, or sign up for a new account and purchase a subscription to continue reading.
Please log in, or sign up for a new account to continue reading.
Thank you for reading! We hope that you continue to enjoy our free content.
Welcome! We hope that you enjoy our free content.
Thank you for reading! On your next view you will be asked to log in or create an account to continue reading.
Thank you for reading! On your next view you will be asked to log in to your subscriber account or create an account and subscribepurchase a subscription to continue reading.
Thank you for signing in! We hope that you continue to enjoy our free content.
Please log in, or sign up for a new account and purchase a subscription to continue reading.
Please purchase a subscription to continue reading.
Your current subscription does not provide access to this content.
You will receive full, ad-free access to HeraldChronicle.com as well as full access to the Electronic Edition of the newspaper.

ONLY $4.99 per month for the first 3 months!
Only $5.99 per month after promotional period.

Or

ONLY $45.99 for a full year
Only $49.99 per year after promotional period.
You will receive full, ad-free access to HeraldChronicle.com as well as full access to the Electronic Edition of the newspaper.

ONLY $2.99 per month for the first 3 months!
Only $3.99 per month after promotional period.

Or

ONLY $33.99 per year for the 1st year
Only $37.99 per year after promotional period.
Home Delivery of print PLUS full access to HeraldChronicle.com as well as full access to the Electronic Edition of the newspaper. INCLUDES ads.

ONLY $3.00 per month for the first 3 months!
Only $4.00 per month after promotional period.

OR

ONLY $40.00 for a full year!
Only $46.00 per year after promotional period.
You will receive full access to HeraldChronicle.com as well as full access to the Electronic Edition of the newspaper. INCLUDES ads.

ONLY $2.49 per month for the first 3 months!
Only $2.99 per month after promotional period.

Or

ONLY $25.99 for a full year!
Only $29.99 per year after promotional period.
Sorry, no promotional deals were found matching that code.
Promotional Rates were found for your code.
Sorry, an error occurred.

do not remove
Rain showers this morning with overcast skies during the afternoon hours. High near 50F. Winds light and variable. Chance of rain 40%..
Cloudy skies. Slight chance of a rain shower. Low near 40F. Winds light and variable.
Updated: November 3, 2021 @ 7:33 am
Paranormal investigators Allison and Robert (Bobby) Stubblefield of Flintville declare that spirits are around us all the time, just wanting to have their voices heard.

The North Middle School Gators beat the Coffee County Raiders 32-26 on the road Monday for their third win of the season.
 Sophia Rayne Phillips
Oct. 30
(StatePoint) There are many benefits to introducing Spanish to your child at an early age. With over 50 million Spanish speakers in the United States, this useful skill has the potential to open social, cultural and professional doors in the future.

NAARDEN, Netherlands–(BUSINESS WIRE)–Nov 3, 2021–
Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, today announced that it has raised $43M in an oversubscribed Series B financing round. The proceeds will be used to prepare for potential registration and commercialization of its lead drug candidate, pridopidine, for patients with Huntington’s Disease (HD) and Amyotrophic Lateral Sclerosis (ALS), as well as to accelerate timelines and expand the Company’s executive team and operations.
The funding round was upsized and led by new investor Sands Capital, alongside Forbion and Morningside. Amplitude Ventures also joined the round as a new investor, in addition to existing investors Sectoral Asset Management, Talisman and the ALS Investment Fund. The Series B financing brings the total capital invested in Prilenia Therapeutics since its founding in September 2018 to $133.5M.
“With the support of this group of leading investors, we are well-capitalized and resourced to continue advancing our programs towards potential registration and commercialization,” said Dr. Michael R. Hayden, CEO and Founder of Prilenia. “The recent completion of patient enrollment in our PROOF-HD Phase 3 clinical trial ahead of schedule and above target enrollment numbers is a significant milestone. We look forward to advancing our programs in both HD and ALS.”
“Prilenia has made tremendous progress since its founding through outstanding execution on all fronts,” said Geert-Jan Mulder, MD, Prilenia Chairman and Managing Partner at Forbion. “We are excited to continue to support the Company on its journey to develop pridopidine as a potential treatment for HD and ALS patients.”
“We are honored and pleased to join this group of outstanding investors in supporting Prilenia on its next stage of progress and growth,” said Michael Ginder, Research Analyst at Sands Capital, who will be joining Prilenia’s Board of Directors.
Pridopidine acts as a highly selective and potent Sigma-1 Receptor (S1R) agonist. Extensive safety data demonstrate pridopidine has a favorable safety and tolerability profile. Currently, pridopidine is the only Phase 3 clinical stage drug candidate assessing HD disease progression as measured by TFC and is also being assessed for treatment of ALS in the HEALEY ALS Phase 2/3 platform trial.
About Pridopidine
Prilenia’s lead asset, Pridopidine is a highly selective and potent Sigma-1 Receptor (S1R) agonist with an established safety and tolerability profile. Pridopidine is orally administered with therapeutic potential in HD, ALS and other neurodegenerative diseases and neurodevelopmental disorders such as Rett and Fragile-X syndromes.
Pridopidine is currently in late-stage clinical development for HD and ALS. Both trials, the global phase 3 clinical trial in HD (PROOF-HD) and the Healey platform trial in ALS are currently active.
About Prilenia
Prilenia is a clinical stage biotech startup founded in 2018 with the purpose of improving the lives of patients and their families by developing treatments for neurodegenerative and neurodevelopmental disorders. Prilenia is backed by a group of well-respected investors including: Forbion, Morningside, Sands Capital, Sectoral Asset Management, Talisman, Amplitude Ventures and the ALS Investment Fund. The Company is based in Naarden, the Netherlands, Herzliya, Israel and Boston, MA in the U.S. For more information visit www.prilenia.com and follow us on Twitter @prileniaTx.
Pridopidine for Huntington’s Disease
Huntington’s Disease (HD) is a fatal, inherited, neurodegenerative disorder. Every offspring of an HD patient has a 50% chance of inheriting the gene. Usually starting at around 40 years of age, HD patients suffer from a movement disorder, progressive functional and cognitive decline, psychiatric disturbances and behavioral symptoms. Following diagnosis, functional, motor and cognitive functions declines, ultimately leading to immobility, dementia and premature death.
Pridopidine has demonstrated maintenance of functional capacity in HD patients, as measured by Total Functional Capacity (TFC), in a post hoc analysis of a phase 2 clinical trial. This effect was most prominent in early-stage HD patients (HD1 and HD2), who showed functional benefit from pridopidine 45 mg, taken twice a day.
Pridopidine demonstrates neuroprotective properties mediated by the S1R in several in vivo and in vitro HD models. In all these models, when the S1R is deleted or an S1R antagonist is used, these neuroprotective properties are eliminated completely. These are comprised of a robust, neuroprotective effect against mutant huntingtin-(mHTT)-induced cell death in human HD induced pluripotent stem cells (iPSCs), and mouse HD cortical neurons. In HD cortico-striatal cultures, pridopidine increases spine density and rescues the aberrant calcium signaling, enhances mitochondrial function and mitigates mHtt-induced ER and oxidative stress, all known features of HD.
Prilenia has been granted orphan drug designation for pridopidine for the treatment of HD in both the U.S. and Europe.
Pridopidine for ALS
Amyotrophic lateral sclerosis, ALS (also known as motor neuron disease), is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 20,000 people in the U.S. ALS causes the degeneration of motor neurons, resulting in progressive muscle weakness and atrophy and eventually death. There are currently two FDA therapies approved specifically for treating ALS—riluzole and edaravone.
Compelling preclinical data supports the potential use of pridopidine as a therapeutic for ALS. Pridopidine exerts its neuroprotective effects via activation of the S1R. Specifically, pridopidine improves BDNF (brain-derived neurotrophic factor) and GDNF (glial cell line-derived neurotrophic factor) axonal transport, restores synaptic activity and neuro-muscular junction (NMJ) function, and increases neuronal survival. In vivo, in ALS models pridopidine reduces toxic protein aggregates and ameliorates muscle fiber wasting. Previous clinical data also suggests that S1R is a promising target for ALS therapy, indicating that S1R activation may enhance bulbar and speech function in ALS patients. The sigma 1 receptor has been genetically validated for ALS, as patients with mutations in this gene develop ALS.
View source version on businesswire.com:https://www.businesswire.com/news/home/20211103005216/en/
CONTACT: Marin Bergman
Ten Bridge Communications
818-516-2746
[email protected]
KEYWORD: NETHERLANDS EUROPE
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH
SOURCE: Prilenia Therapeutics B.V.
Copyright Business Wire 2021.
PUB: 11/03/2021 07:00 AM/DISC: 11/03/2021 07:02 AM
http://www.businesswire.com/news/home/20211103005216/en
Copyright Business Wire 2021.
Sorry, there are no recent results for popular videos.
Get up-to-the-minute news sent straight to your device.

source